Journal: Acta Pharmaceutica Sinica. B

Article Title: An immunostimulant nanomedicine enhances radioimmunotherapy by remodeling the tumor immunosuppressive landscape after radiotherapy

doi: 10.1016/j.apsb.2025.11.012

Figure Lengend Snippet: Immunosuppression after radiotherapy promotes breast cancer progression. Tumor growth curves (A) and weights (B) of mice before and after RT ( n = 6). (C) Survival curve of mice after different treatments ( n = 6). Tumor growth curves (D) and weights (E) of mice treated with RT and RT plus α -PD-L1 ( n = 6). (F) Survival curve of mice after different treatments ( n = 6). (G) Cluster analysis of differential expression genes between untreated and RT-treated tumors 48 h post-RT ( n = 3). (H) Gene Ontology (GO) analysis of tumor tissues before and after RT (select the top 10 for each item). (I) Heat map of differentially expressed genes related to apoptosis and immune suppression ( n = 3). (J) Immunofluorescence staining images of tumor tissue in saline and RT groups (scale bar = 20 μm). (K) Quantitative analysis of tumor-infiltrating CD45 + cells ( n = 6). Representative flow cytometry images (M) and quantitative analysis (L) of tumor-infiltrating MDSCs ( n = 6). (N) The TUNEL staining of tumor section (scale: 25 μm). (O) Adenosine content detection in tumor tissue ( n = 6). Data are presented as mean ± SD. ∗∗∗∗ P < 0.0001 determined by Student’s t-test.

Article Snippet: InVivo MAb anti-mouse PD-L1 was purchased from Bioxcell (USA).

Techniques: Quantitative Proteomics, Immunofluorescence, Staining, Saline, Flow Cytometry, TUNEL Assay

Journal: Acta Pharmaceutica Sinica. B

Article Title: An immunostimulant nanomedicine enhances radioimmunotherapy by remodeling the tumor immunosuppressive landscape after radiotherapy

doi: 10.1016/j.apsb.2025.11.012

Figure Lengend Snippet: FD@ATRA-enhanced radiotherapy combined with α -PD-L1 to enhance the efficacy of large-volume tumors. (A) Schematic diagram of the therapeutic process for evaluating the anti-tumor effects in a bilateral 4T1 tumor-bearing mouse model of large volume. (B) Distant tumor growth curves of mice after different treatments ( n = 5). (C) In vitro images of the distant tumors ( n = 5). (D) In vitro distant tumors mass ( n = 5). (E) Immunohistochemical staining of CD3 in tumor tissue slices after different treatments (scale bars = 100 μm). The images below were the corresponding enlarged parts (scale bars = 25 μm). (F) Immunohistochemical staining of CD8 in tumor tissue slices after various treatments (scale bars = 100 μm). The images below were the corresponding enlarged parts (scale bars = 25 μm). Data are presented as mean ± SD. ∗∗∗ P < 0.001, and ∗∗∗∗ P < 0.0001 determined by Student’s t -test.

Article Snippet: InVivo MAb anti-mouse PD-L1 was purchased from Bioxcell (USA).

Techniques: In Vitro, Immunohistochemical staining, Staining

Journal: Cell & Bioscience

Article Title: M1-BMDMs with Wnt5a deletion attenuate liver fibrosis by suppression of Wnt5a/Frizzled 2 axis in hepatic progenitors

doi: 10.1186/s13578-025-01467-x

Figure Lengend Snippet: M1-BMDM Wnt5a −KD injection inhibits HPCs activation and DR. ( a ) CK7 and CK19 immunostaining (×200). ( b ) EpCam and Sox9 immunostaining (×200). ( c ) Protein and mRNA expression levels of CK7, CK19, EpCAM and SOX9. ( d ) OV6/CK7 immunofluorescence co-staining (×400), and the costaining cells ratio of OV6/CK7. ( e ) OV6/CK19 immunofluorescence co-staining (×400), and the costaining cells ratio of OV6/CK19. ( f ) EpCam/CK19 immunofluorescence co-staining (×400), and the costaining cells ratio of EpCam/CK19. ( g ) Sox9/CK19 immunofluorescence co-staining (×400), and the costaining cells ratio of Sox9/CK19. * P < 0.05; ** P < 0.01

Article Snippet: The following antibodies were utilized for immunostaining and immunoblot analysis: rabbit polyclonal antibody anti-CD68 (ab125212), mouse monoclonal antibody anti-alpha smooth muscle actin (α-SMA; ab5694/ab124964), rabbit polyclonal antibodies anti-cytokeratin 7 (CK7; ab181598), EpCam (ab71916) and Sox9 (ab185230) (Abcam, Cambridge, UK); mouse monoclonal antibodies anti-transforming growth factor β1 (TGF-β1; sc-130348), OV6 (sc-101863) and Wnt5a (sc-365370) (Santa Cruz Biotechnology, Inc., CA, USA); mouse monoclonal antibody anti-Wnt5a ( SAB53430 ) (Signal way Antibody, Maryland, USA); mouse monoclonal antibody anti-Frizzled 2 (Fzd2; 24272-1-AP), rabbit polyclonal antibodies anti-cytokeratin 19 (CK19; 10712-1-AP) and glyceraldehyde-3-phosphate dehydrogenase antibody (GAPDH) (Proteintech Group Inc., Chicago, IL, USA); IRDye 800CW-conjugated donkey anti-mouse IgG (H + L) and IRDye 680RD-conjugated donkey anti-rabbit IgG (H + L) (LI-COR Bioscience, San Jose, CA, USA); 4’,6-diamidino-2-phenylindole (DAPI; C1002) (Beyotime, Shanghai, China).

Techniques: Injection, Activation Assay, Immunostaining, Expressing, Immunofluorescence, Staining

Journal: Cell & Bioscience

Article Title: M1-BMDMs with Wnt5a deletion attenuate liver fibrosis by suppression of Wnt5a/Frizzled 2 axis in hepatic progenitors

doi: 10.1186/s13578-025-01467-x

Figure Lengend Snippet: M1-BMDM Wnt5a −OE injection promotes HPCs activation and DR. ( a ) CK7 and CK19 immunostaining (×200). ( b ) EpCam and Sox9 immunostaining (×200). ( c ) Protein and mRNA expression levels of CK7, CK19, EpCam and Sox9. ( d ) Immunofluorescence costaining of OV6/CK7 (×400) and the costaining area ratio (%). ( e ) Immunofluorescence costaining of OV6/CK19 (×400) and the costaining area ratio (%). ( f ) Immunofluorescence costaining of EpCam/CK19 (×400) and the costaining area ratio (%). ( g ) Immunofluorescence costaining of Sox9/CK19 (×400) and the costaining area ratio (%). * P < 0.05; ** P < 0.01

Article Snippet: The following antibodies were utilized for immunostaining and immunoblot analysis: rabbit polyclonal antibody anti-CD68 (ab125212), mouse monoclonal antibody anti-alpha smooth muscle actin (α-SMA; ab5694/ab124964), rabbit polyclonal antibodies anti-cytokeratin 7 (CK7; ab181598), EpCam (ab71916) and Sox9 (ab185230) (Abcam, Cambridge, UK); mouse monoclonal antibodies anti-transforming growth factor β1 (TGF-β1; sc-130348), OV6 (sc-101863) and Wnt5a (sc-365370) (Santa Cruz Biotechnology, Inc., CA, USA); mouse monoclonal antibody anti-Wnt5a ( SAB53430 ) (Signal way Antibody, Maryland, USA); mouse monoclonal antibody anti-Frizzled 2 (Fzd2; 24272-1-AP), rabbit polyclonal antibodies anti-cytokeratin 19 (CK19; 10712-1-AP) and glyceraldehyde-3-phosphate dehydrogenase antibody (GAPDH) (Proteintech Group Inc., Chicago, IL, USA); IRDye 800CW-conjugated donkey anti-mouse IgG (H + L) and IRDye 680RD-conjugated donkey anti-rabbit IgG (H + L) (LI-COR Bioscience, San Jose, CA, USA); 4’,6-diamidino-2-phenylindole (DAPI; C1002) (Beyotime, Shanghai, China).

Techniques: Injection, Activation Assay, Immunostaining, Expressing, Immunofluorescence

Journal: Journal of Nanobiotechnology

Article Title: Inverse-designed plasmonic biosensors with LSPR-SPP-wood anomaly coupling enhanced for biomolecular analysis

doi: 10.1186/s12951-025-03930-w

Figure Lengend Snippet: High-throughput affinity sensing platform for ADC drug development. ( a ) The association process of incubating PD-1 on the chip to detect Sintilimab. ( b ) The long-time dissociation process of PD-1 with Sintilimab. ( c ) Dynamic real-time and fitting curves of the association and dissociation phases of the interaction between PD-1 and Sintilimab. ( d ) Schematic diagram of the high-throughput antibody affinity detection protocol, with each group, repeated three times in the three samples tested, and the concentration of A-H in each column decreasing incrementally. ( e ) Schematic diagram of the main events in the antibody drug fishing and affinity detection process. ( f-h ) Dynamic real-time and fitting curves of the association and dissociation phases for Polatuzumab with CD79B, Adalimumab with TNF-α, and Sacituzumab govitecan with TROP2, detected using the unoptimized sensor. ( i-k ) Dynamic real-time and fitting curves of the association and dissociation phases for Polatuzumab with CD79B, Adalimumab with TNF-α, and Sacituzumab govitecan with TROP2, detected using the optimized IDMM-SPR sensor

Article Snippet: Bovine serum albumin (BSA), Phosphate-buffered saline (PBST), 11-mercaptoundecanoic acid (MUA), 1-ethyl3-(dimethylaminopropyl) carbodiimide (EDC), N-hydroxysuccinimide (NHS), Dimethyl Sulfoxide (DMSO), Fish gelatin,, ethanolamine, and phosphate-buffered saline (PBS) buffer, Polyethylene glycol 2000 (PEG) were purchased from Sigma-Aldrich; Protein A, IgG, CRP, and CRP ab, hTGFBR1 were purchased from monoclonal anti-CRP capture and detection antibodies were purchased from Beijing Sino Biological, Inc. (Beijing, China); Sintilimab, Adalimumab, Polatuzumab, Sacituzumab, PD-1, TNF-α, CD79B, TROP2, Quercetin were purchased from MedChemExpress.

Techniques: High Throughput Screening Assay, Concentration Assay